公开(公告)号：EP3351628A1

公开(公告)日：2018-07-25

申请号：EP18160105.5

申请日：2009-10-26

申请人： The Government of The United States of America as represented by The Secretary, Department of Health and Human Services

发明人： TOWNER, Jonathan, S ,  NICHOL, Stuart, T ,  COMER, James, A. ,  KSIAZEK, Thomas, G ,  ROLLIN, Pierre, E.

IPC分类号： C12N7/01 ,  C12N15/40 ,  C07K14/08 ,  C07K16/10 ,  G01N33/68 ,  A61K39/12

CPC分类号： C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/542 ,  A61K2039/543 ,  C07K14/005 ,  C07K16/10 ,  C07K2317/76 ,  C12N2760/14121 ,  C12N2760/14134 ,  C12N2760/14143 ,  C12N2760/14145 ,  C12N2810/6072 ,  C12Q1/701 ,  G01N33/56983 ,  G01N2333/08

摘要： Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

公开(公告)号：EP2994754B1

公开(公告)日：2018-07-25

申请号：EP14729563.8

申请日：2014-05-12

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： KHUDYAKOV, Yury, E. ,  OBRIADINA, Anna

IPC分类号： G01N33/50

CPC分类号： G01N33/5767 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24231 ,  G01N2333/186 ,  G01N2469/20

摘要： Compositions and processes are provided for the robust detection of hepatitis C virus in a sample. Compositions include amino acid sequences of HCV core region including or exclusive to residues 14-31 or 50-90 of the HCV core protein. Also provided are processes of detecting HCV in a sample whereby the provided peptides are optionally used alone or in conjunction with antibodies that do not recognize the peptides so that detection is independent of seroconversion in a subject. Using the compositions and processes, HCV can be detected in a sample prior to or following seroconversion leading to robust HCV detection and diagnosis.

公开(公告)号：EP3331878A1

公开(公告)日：2018-06-13

申请号：EP16751125.2

申请日：2016-08-05

申请人： Arnér, Elias, Set Jenö ,  The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： STAFFORD, William, Chester ,  COUSSENS, Nathan, Patrick ,  LUCI, Diane, Karen ,  MALONEY, David, Joseph ,  SIMEONOV, Anton ,  JADHAV, Ajit ,  DEXHEIMER, Thomas, S. ,  ARNÉR, Elias, Set Jenö

IPC分类号： C07D413/06 ,  A61K31/501 ,  A61P35/00

CPC分类号： C07D413/06

摘要： There is provided compounds of formula (I) or pharmaceutically-acceptable salts thereof, wherein W, X, Y, Z, R1, R2 and R3 have meanings provided in the description, which compounds are useful in the treatment of cancers.

公开(公告)号：EP3328994A1

公开(公告)日：2018-06-06

申请号：EP16833684.0

申请日：2016-08-01

申请人： Memorial Sloan-Kettering Cancer Center ,  The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： SADELAIN, Michel ,  BENJAMIN, Reuben ,  DIMITROV, Dimiter, S. ,  FENG, Yang

IPC分类号： C12N5/0783 ,  C07K14/725 ,  C07K16/30

CPC分类号： C07K16/2803 ,  A61K35/17 ,  A61K2039/505 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70

摘要： The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

公开(公告)号：EP3328399A1

公开(公告)日：2018-06-06

申请号：EP16833645.1

申请日：2016-07-29

申请人： Regents of the University of Minnesota ,  Intima Bioscience, Inc. ,  The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： MORIARITY, Branden ,  WEBBER, Beau ,  MCIVOR, Scott, R. ,  LARGAESPADA, David ,  CHOUDHRY, Modassir ,  ROSENBERG, Steven A. ,  RESTIFO, Nicholas P. ,  PALMER, Douglas C.

IPC分类号： A61K35/00 ,  A61K35/17 ,  A61K35/28 ,  A61K38/00 ,  C07H21/04 ,  C07K14/725

CPC分类号： A61K35/17 ,  C07K14/4718 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/7158 ,  C12N5/0636 ,  C12N9/22 ,  C12N9/96 ,  C12N15/113 ,  C12N15/87 ,  C12N15/907 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80 ,  Y02A50/463

摘要： Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.

公开(公告)号：EP2836591B1

公开(公告)日：2018-06-06

申请号：EP13718439.6

申请日：2013-04-09

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： ROBERTS, David, D. ,  KAUR, Sukhbir ,  ISENBERG, Jeffrey, S.

IPC分类号： C12N5/074 ,  C12N5/0789 ,  C12N5/079

CPC分类号： C12N5/0696 ,  C12N5/0618 ,  C12N5/0647 ,  C12N2501/599

摘要： This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.

公开(公告)号：EP1654370B1

公开(公告)日：2018-05-30

申请号：EP04779743.6

申请日：2004-08-02

申请人： GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： NABEL, Gary, J. ,  SULLIVAN, Nancy, J. ,  GEISBERT, Thomas, W. ,  JAHRLING, Peter, B.

IPC分类号： C12N15/861 ,  A61K39/12 ,  C12N15/86

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C07K16/1081 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2760/14134 ,  C12N2760/14171 ,  Y02A50/464

摘要： The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form.

公开(公告)号：EP3314266A1

公开(公告)日：2018-05-02

申请号：EP16739339.6

申请日：2016-06-29

申请人： The United States Of America, As Represented By The Secretary, Department Of Health And Human Services

发明人： PATEL, Dhaval, T. ,  KRAUSZ, Kristopher, W. ,  GONZALEZ, Frank, J ,  KEBEBEW, Electron ,  THOMPSON, Matthew

IPC分类号： G01N33/574 ,  G01N33/68

CPC分类号： G01N33/57438 ,  G01N33/6812 ,  G01N2570/00 ,  G01N2800/56

摘要： Disclosed herein are methods of diagnosing and treating a malignant adrenocortical tumor, including adrenocortical carcinoma. In some examples, methods of diagnosing a malignant adrenocortical tumor include measuring creatine riboside, L-tryptophan, Nε,Nε,Nε-trimethyl-L-lysine and 3-methylhistidine in a biological sample obtained from a subject with an adrenocortical tumor and identifying an increase in creatine riboside and a decrease in L-tryptophan, Nε,Nε,Nε-trimethyl-L-lysine and 3-methylhistidine in the biological sample when compared to a control or reference value for each molecule indicates a malignant adrenocortical tumor. Methods of treatment and evaluating the effectiveness of an agent for treating a malignant adrenocortical tumor are also disclosed. Additionally, kits, assays and devices for characterizing adrenocortical tumors are provided.

公开(公告)号：EP2689022B1

公开(公告)日：2018-04-25

申请号：EP12760251.4

申请日：2012-03-21

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services ,  Elixirgen, LLC

发明人： KO, Minoru, S.H. ,  AMANO, Tomokazu

IPC分类号： C07K14/72 ,  C07K14/00 ,  C07K14/47 ,  C07K14/705

CPC分类号： C07K14/47 ,  C07K14/70567 ,  C07K14/721 ,  C07K2319/00

摘要： Described herein is the finding that increasing the frequency of Zscan4 activation in mouse ES cells not only enhances, but also maintains their developmental potency in long-term cell culture. Particularly disclosed herein is the finding that the constitutive presence of Zscan4-ERT2, even in the absence of its usual activator tamoxifen, can increase the frequency of endogenous Zscan4 activation in ES cells, resulting in the increase of developmental potency of the ES cells. Accordingly, provided herein are Zscan4-ERT2 fusion proteins and nucleic acid molecules and vectors encoding Zscan4-ERT2 fusion proteins. Further provided are methods of prolonging and/or enhancing stem cell plmipotency using the disclosed Zscan4-ERT2 nucleic acid molecules and fusion proteins.

公开(公告)号：EP3302508A1

公开(公告)日：2018-04-11

申请号：EP16800847.2

申请日：2016-05-27

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services ,  Kite Pharma, Inc.

发明人： BOT, Adrian ,  WIEZOREK, Jeffrey ,  JAIN, Rajul ,  KOCHENDERFER, James ,  ROSENBERG, Steven

IPC分类号： A61K35/26 ,  C12N5/0783 ,  C12N5/0784

CPC分类号： A61K35/17 ,  A61K31/664 ,  A61K31/675 ,  A61K31/7076 ,  A61K38/2013 ,  A61K38/2053 ,  A61K45/06 ,  A61P35/02 ,  A61K2300/00

摘要： The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.